Valeant Pharmaceuticals International

The once-gilded hedge fund manager, who posted big losses in several of his hedge funds last year, is managing a fraction of what he did at the firm’s peak.
The long-short manager, which recently exited a high-profile short, has set its sights on TransDigm Group, a defense contractor that has enjoyed strong support from the Tiger crowd.
Valeant’s stock is down 20 percent for the year and has dropped more than 31 percent from its 2017 high.
PointState Capital sold all of its roughly 8.5 million shares in pharmaceutical company.
RBA makes rate announcement before its changing of the guard; Valeant to announce results; Chicago gets down with the blues.